Clinical Trials Directory

Trials / Unknown

UnknownNCT02958579

a Population Based Study on Metabolic Syndrome Complications, and Mortality

A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study

Status
Unknown
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Tehran University of Medical Sciences · Academic / Other
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Metabolic syndrome (MetS) is recognized as clustering of a number of components including hypertension, hypertriglyceridemia, low serum high-density lipoprotein cholesterol (HDL-C), impaired glucose metabolism (IGM), and abdominal obesity. It has been tightly linked to thrombotic vascular events including coronary heart disease (CHD). Worldwide prevalence of MetS is on the rise. People living in Iran, a country located in the Middle-East region, have distinct behavioral, environmental and social exposures which certainly affect the prevalence and incidence of metabolic syndrome and its comorbidities.We hypothesized that these factors may affect the course of metabolic syndrome and the burden that it imposes to the community. The purposes of MetSCoM are as follows; 1. To find the incidence of T2D, microvascular complications of T2D (diabetic retinopathy, diabetic neuropathy and diabetic kidney disease), CVD, and mortality rate of subjects metabolic syndrome. 2. To find the association of baseline, mean value during follow up visits and visit to visit variability in anthropometric variables and several metabolic laboratory variables with metabolic syndrome and its complications. 3. To find the effect of behavioral variables and environmental exposures on the course of metabolic syndrome. 4. To identify the best anthropometric, laboratory, life-style and environmental predictors of CVD and mortality rate in subjects with metabolic syndrome. 5. To estimate the economic burden of metabolic syndrome and its related

Detailed description

A biphasic observational study will be conducted on participants with any component of metabolic syndrome in Tehran, Iran. Phase one of the study is a cross-sectional study, while the second phase is a prospective cohort. In phase one of study, the prevalence of any metabolic disorder will be estimated in the study population and the association of biochemical variables, behavioral and environmental variables with each metabolic disorder will be investigated. Afterwards, through the phase two, those with any component of metabolic syndrome will be followed to record the incidence of diabetes, vascular complications of diabetes, non-alcoholic fatty liver disease, (NAFLD), cancers, mortality rate and finally estimation of economic burden of metabolic syndrome and its components in study population. Participants will be recruited from four health surveillance centers located at East, West, North and South of Tehran, the capital city of Iran. The latitude of Tehran is 35°41' North, and 51°25' East. Participants will be followed for at least 10 years and we plan to extend this time if possible. Anthropometric, biochemical, behavioral and meteorological measurements will done on scheduled timeline.

Conditions

Interventions

TypeNameDescription
OTHERNo intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.

Timeline

Start date
2005-01-01
Primary completion
2017-01-01
Completion
2020-01-01
First posted
2016-11-08
Last updated
2016-11-08

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT02958579. Inclusion in this directory is not an endorsement.